Obermatt
See Similar Stocks →

Alumis

NSQ:ALMS · US0223071020
PharmaceuticalsSmall

360

22
Profit price76
Owner Earnings Yield1
Dividend Yield1
Price/Sales7
EV / Gross Profit1
Price/Book24
Return on Capital1
Cash Return on Capital6
Return on Equity8
Profit margins4
Accruals13
Owner Earnings Margin1
Sales growth9
Profit growth1
Reinvestment64
Price momentum98
Debt load54
Refinancing24
Debt Payback1
Liquidity69
Analyst ratings67
Opinion Changes32
Price Target Upside90
Market mood8
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Alumis doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2021
Employees230
Websitealumis.com
ISINUS0223071020
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
OphthalmologyGeneticsDermatologyChronic DiseasesImmunologyRheumatologyNeurologyCentral Nervous SystemBiotechnologyHealth CareLife Science

Description

Alumis Inc. operates as a clinical stage biopharmaceutical company. The company, with an initial focus on developing its two Tyrosine Kinase 2 (TYK2) inhibitors, envudeucitinib (envu), formerly known as ESK-001, a second-generation inhibitor that it…

Analysis

Story stock

Alumis Inc. trades at an expensive price on a weak set of business metrics, a combination we flag as a story stock.

Valuation data is not available for this company.

Growth is moderate; the safety picture is adequate. The company scores 6/20 on our value-creation score: not creating value. Analysts lean positive.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
4
2026

All-time high

58

Mar 2026

All-time low

4

Jun 2026

Average rank

31

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
7
—
—
—
Price/Earnings
73
—
—
—
Price/Book
24
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
19
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Alumis with its peers
Ventyx Biosciences
NSQ:VTYX
51
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Biogen Idec
NSQ:BIIB
82
CountryUSA
IndustryBiotechnology
SizeX-Large
Full Stock Analysis →
Eton Pharmaceuticals
NMQ:ETON
70
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Omeros
NMQ:OMER
29
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Aclaris Therapeutics
NSQ:ACRS
28
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Supernus Pharma
NMQ:SUPN
81
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →